vs
CARLISLE COMPANIES INC（CSL）与Steris（STE）财务数据对比。点击上方公司名可切换其他公司
Steris的季度营收约是CARLISLE COMPANIES INC的1.4倍（$1.5B vs $1.1B），Steris净利率更高（12.9% vs 12.1%，领先0.8%），Steris同比增速更快（9.2% vs -4.0%），Steris自由现金流更多（$199.5M vs $-73.0M），过去两年Steris的营收复合增速更高（15.8% vs -14.8%）
卡莱尔公司是专业建筑产品供应商，聚焦于提升建筑能效与稳固性，面向商业建筑领域生产销售单层屋面产品、质保系统及配套配件，旗下设有卡莱尔建筑材料、卡莱尔防水技术两大业务板块，产品涵盖防潮材料、屋面防护层等多个品类。
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
CSL vs STE — 直观对比
营收规模更大
STE
是对方的1.4倍
$1.1B
营收增速更快
STE
高出13.2%
-4.0%
净利率更高
STE
高出0.8%
12.1%
自由现金流更多
STE
多$272.5M
$-73.0M
两年增速更快
STE
近两年复合增速
-14.8%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.5B |
| 净利润 | $127.7M | $192.9M |
| 毛利率 | 34.5% | 43.8% |
| 营业利润率 | 17.1% | 18.3% |
| 净利率 | 12.1% | 12.9% |
| 营收同比 | -4.0% | 9.2% |
| 净利润同比 | -10.9% | 11.2% |
| 每股收益（稀释后） | $3.10 | $1.96 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSLSTE
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.3B | $1.5B | ||
| Q2 25 | $1.4B | $1.4B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $1.1B | $1.4B | ||
| Q3 24 | $1.3B | $1.3B | ||
| Q2 24 | $1.5B | $1.3B |
净利润CSLSTE
| Q1 26 | $127.7M | — | ||
| Q4 25 | $127.4M | $192.9M | ||
| Q3 25 | $214.2M | $191.9M | ||
| Q2 25 | $255.8M | $177.4M | ||
| Q1 25 | $143.3M | $145.7M | ||
| Q4 24 | $162.8M | $173.5M | ||
| Q3 24 | $244.3M | $150.0M | ||
| Q2 24 | $712.4M | $145.4M |
毛利率CSLSTE
| Q1 26 | 34.5% | — | ||
| Q4 25 | 33.8% | 43.8% | ||
| Q3 25 | 36.0% | 44.2% | ||
| Q2 25 | 37.3% | 45.1% | ||
| Q1 25 | 35.2% | 43.3% | ||
| Q4 24 | 36.1% | 44.5% | ||
| Q3 24 | 38.6% | 43.6% | ||
| Q2 24 | 39.2% | 44.7% |
营业利润率CSLSTE
| Q1 26 | 17.1% | — | ||
| Q4 25 | 16.8% | 18.3% | ||
| Q3 25 | 21.8% | 18.2% | ||
| Q2 25 | 23.1% | 17.7% | ||
| Q1 25 | 16.8% | 14.6% | ||
| Q4 24 | 19.9% | 17.9% | ||
| Q3 24 | 23.7% | 16.5% | ||
| Q2 24 | 26.0% | 14.5% |
净利率CSLSTE
| Q1 26 | 12.1% | — | ||
| Q4 25 | 11.3% | 12.9% | ||
| Q3 25 | 15.9% | 13.1% | ||
| Q2 25 | 17.6% | 12.8% | ||
| Q1 25 | 13.1% | 9.8% | ||
| Q4 24 | 14.5% | 12.7% | ||
| Q3 24 | 18.3% | 11.3% | ||
| Q2 24 | 49.1% | 11.4% |
每股收益（稀释后）CSLSTE
| Q1 26 | $3.10 | — | ||
| Q4 25 | $3.06 | $1.96 | ||
| Q3 25 | $4.98 | $1.94 | ||
| Q2 25 | $5.88 | $1.79 | ||
| Q1 25 | $3.20 | $1.48 | ||
| Q4 24 | $3.76 | $1.75 | ||
| Q3 24 | $5.25 | $1.51 | ||
| Q2 24 | $14.84 | $1.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $771.3M | $423.7M |
| 总债务越低越好 | — | $1.9B |
| 股东权益账面价值 | $1.7B | $7.2B |
| 总资产 | — | $10.6B |
| 负债/权益比越低杠杆越低 | — | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资CSLSTE
| Q1 26 | $771.3M | — | ||
| Q4 25 | $1.1B | $423.7M | ||
| Q3 25 | $1.1B | $319.2M | ||
| Q2 25 | $68.4M | $279.7M | ||
| Q1 25 | $220.2M | $171.7M | ||
| Q4 24 | $753.5M | $155.2M | ||
| Q3 24 | $1.5B | $172.2M | ||
| Q2 24 | $1.7B | $198.3M |
总债务CSLSTE
| Q1 26 | — | — | ||
| Q4 25 | $2.9B | $1.9B | ||
| Q3 25 | $2.9B | $1.9B | ||
| Q2 25 | $1.9B | $1.9B | ||
| Q1 25 | $1.9B | $1.9B | ||
| Q4 24 | $1.9B | $2.0B | ||
| Q3 24 | $2.3B | $2.2B | ||
| Q2 24 | $2.3B | $2.2B |
股东权益CSLSTE
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.8B | $7.2B | ||
| Q3 25 | $2.0B | $7.0B | ||
| Q2 25 | $2.1B | $7.0B | ||
| Q1 25 | $2.2B | $6.6B | ||
| Q4 24 | $2.5B | $6.4B | ||
| Q3 24 | $2.8B | $6.6B | ||
| Q2 24 | $3.0B | $6.4B |
总资产CSLSTE
| Q1 26 | — | — | ||
| Q4 25 | $6.3B | $10.6B | ||
| Q3 25 | $6.5B | $10.4B | ||
| Q2 25 | $5.5B | $10.4B | ||
| Q1 25 | $5.5B | $10.1B | ||
| Q4 24 | $5.8B | $10.0B | ||
| Q3 24 | $6.5B | $10.2B | ||
| Q2 24 | $6.7B | $10.1B |
负债/权益比CSLSTE
| Q1 26 | — | — | ||
| Q4 25 | 1.61× | 0.27× | ||
| Q3 25 | 1.45× | 0.27× | ||
| Q2 25 | 0.89× | 0.27× | ||
| Q1 25 | 0.87× | 0.29× | ||
| Q4 24 | 0.77× | 0.32× | ||
| Q3 24 | 0.83× | 0.33× | ||
| Q2 24 | 0.76× | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $298.2M |
| 自由现金流经营现金流 - 资本支出 | $-73.0M | $199.5M |
| 自由现金流率自由现金流/营收 | -6.9% | 13.3% |
| 资本支出强度资本支出/营收 | 2.7% | 6.6% |
| 现金转化率经营现金流/净利润 | — | 1.55× |
| 过去12个月自由现金流最近4个季度 | $924.8M | $917.1M |
8季度趋势，按日历期对齐
经营现金流CSLSTE
| Q1 26 | — | — | ||
| Q4 25 | $386.0M | $298.2M | ||
| Q3 25 | $426.9M | $287.8M | ||
| Q2 25 | $287.1M | $420.0M | ||
| Q1 25 | $1.8M | $260.8M | ||
| Q4 24 | $370.6M | $332.8M | ||
| Q3 24 | $312.8M | $250.7M | ||
| Q2 24 | $183.4M | $303.7M |
自由现金流CSLSTE
| Q1 26 | $-73.0M | — | ||
| Q4 25 | $346.1M | $199.5M | ||
| Q3 25 | $393.4M | $201.3M | ||
| Q2 25 | $258.3M | $326.4M | ||
| Q1 25 | $-27.2M | $189.9M | ||
| Q4 24 | $334.0M | $243.6M | ||
| Q3 24 | $293.5M | $148.8M | ||
| Q2 24 | $158.5M | $195.7M |
自由现金流率CSLSTE
| Q1 26 | -6.9% | — | ||
| Q4 25 | 30.7% | 13.3% | ||
| Q3 25 | 29.2% | 13.8% | ||
| Q2 25 | 17.8% | 23.5% | ||
| Q1 25 | -2.5% | 12.8% | ||
| Q4 24 | 29.7% | 17.8% | ||
| Q3 24 | 22.0% | 11.2% | ||
| Q2 24 | 10.9% | 15.3% |
资本支出强度CSLSTE
| Q1 26 | 2.7% | — | ||
| Q4 25 | 3.5% | 6.6% | ||
| Q3 25 | 2.5% | 5.9% | ||
| Q2 25 | 2.0% | 6.7% | ||
| Q1 25 | 2.6% | 4.8% | ||
| Q4 24 | 3.3% | 6.5% | ||
| Q3 24 | 1.4% | 7.7% | ||
| Q2 24 | 1.7% | 8.4% |
现金转化率CSLSTE
| Q1 26 | — | — | ||
| Q4 25 | 3.03× | 1.55× | ||
| Q3 25 | 1.99× | 1.50× | ||
| Q2 25 | 1.12× | 2.37× | ||
| Q1 25 | 0.01× | 1.79× | ||
| Q4 24 | 2.28× | 1.92× | ||
| Q3 24 | 1.28× | 1.67× | ||
| Q2 24 | 0.26× | 2.09× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSL
| CCM | $758.0M | 72% |
| CWT | $294.0M | 28% |
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
